Seikagaku takes forward Can-Fite's arthritis therapy
This article was originally published in Scrip
Seikagaku has begun the clinical development in Japan of Can-Fite BioPharma's lead compound, SI-615 (CF101), for the treatment of rheumatoid arthritis (RA).
You may also be interested in...
Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.
A resolution in a long-running patent dispute, expansion of coronavirus vaccine production, drug development trends over the past decade, hematological malignancies in a clinical trial, and the last instalment in the Scrip Asks series all feature in this week's podcast version of Scrip's Five Must-Know Things.
US research-based association says move to annual drug repricing undermines country’s recent efforts to support innovation and again calls for inclusive discussions around broad health system reforms to create funding headroom.